Page last updated: 2024-08-24

topotecan and Lung Neoplasms

topotecan has been researched along with Lung Neoplasms in 329 studies

Research

Studies (329)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	54 (16.41)	18.2507
2000's	170 (51.67)	29.6817
2010's	81 (24.62)	24.3611
2020's	24 (7.29)	2.80

Authors

Authors	Studies
Boehm, JC; Caranfa, MJ; Faucette, LF; Gallagher, G; Hecht, SM; Holden, KG; Jakas, DR; Johnson, RK; Kingsbury, WD; McCabe, FL	1
Carenini, N; Dallavalle, S; De Cesare, M; Ferrari, A; Merlini, L; Penco, S; Perego, P; Pratesi, G; Zunino, F	1
Beretta, GL; Dallavalle, S; Gattinoni, S; Mazzini, S; Merlini, L; Scaglioni, L; Tinelli, S; Zunino, F	1
Dong, G; Fang, K; Guo, Z; Li, J; Liu, Y; Miao, Z; Sheng, C; Wang, S; Wu, S; Wu, Y; Yao, J; Zhang, W; Zhu, L; Zhu, S; Zhuang, C	1
Chepanova, AA; Kaledin, VI; Lavrik, OI; Leung, E; Leung, IKH; Luzina, OA; Nikolin, VP; Patel, J; Popova, NA; Reynisson, J; Salakhutdinov, NF; Sokolov, DN; Volcho, KP; Zafar, A; Zakharenko, AL; Zakharova, OD	1
Dai, X; Jiang, T; Li, J; Qi, X; Wu, G; Yin, R; Yu, R; Zhang, G	1
Fang, Z; He, M; Liu, M; Liu, Q; Peng, J; Wei, Y; Wu, B; Yi, F; Zhang, W	1
Cao, GZ; Hua, JH; Lin, WC; Lv, XT; Ma, LY; Yin, YP	1
Esiashvili, N; Olson, T; Rapkin, L; Reisner, A; Shim, J	1
Pommier, Y; Schultz, CW; Sun, Y; Thomas, A; Zhang, Y	1
Beelen, A; Curd, L; Goti, V; Horton, JK; Li, C; Sale, M; Tao, W	1
Weber, JP; Wermke, M	1
Gao, J; Li, X; Liu, Z; Teng, Y; Yin, P; Yu, P	1
Adeyemi, A; Boccuti, A; Caisip, C; Hanvesakul, R; Jansen, JP; Naveh, N; Park, JE; Rengarajan, B; Wilson, FR	1
Aljumaily, R; Burris Iii, HA; Johnson, ML; Jones, SF; Patel, MR; Spigel, DR	1
Gerner-Rasmussen, J; Hansen, O; Holm, B; Jeppesen, N; Langer, SW; Mau-Sørensen, M; McCulloch, T; Nielsen, HA; Nyhus, CH; Rytter, C; Wedervang, K	1
Chang, J; Li, YN; Liu, ZL; Yao, YM; Zhang, YT; Zhong, XD	1
Cramer-van der Welle, CM; Groen, HJM; Schramel, FMNH; van de Garde, EMW; van Leeuwen, AS	1
Besse, B; Blackhall, F; Califano, R; Cappuzzo, F; de Marinis, F; De Ruysscher, D; Felip, E; Früh, M; Garrido, P; Novello, S; O'Brien, M; Panje, CM; Paz Ares, L; Putora, PM; Reck, M; Westeel, V	1
Cui, H; Ma, Q; Shi, W; Xue, G; Zhang, J; Zhang, L	1
Arrieta, O; Lara-Mejía, L; Zatarain-Barrón, ZL	1
Basse, C; El Kaddissi, A	1
Chen, H; Horita, N; Takeshi, K	1
Baize, N; Chouaid, C; Monnet, I	1
Blackhall, F; Caffrey, L; Cappuzzo, F; Cetnar, J; Cho, BC; Erman, M; Greillier, L; Groen, H; Hansen, K; Jao, K; Kato, T; Komarnitsky, P; Langer, SW; Luo, Y; Majem, M; Nackaerts, K; Okamoto, I; Penkov, K; Reguart, N; Reinmuth, N; Schuette, W; Sun, Z; Syrigos, K; Tanwani, P	1
Drapkin, BJ; Minna, JD	1
Belinsky, SA; Burke, M; Chen, W; Dubose, D; Dye, WW; Kuehl, PJ; Revelli, DA; Tessema, M; Yingling, CM	1
Elloumi, F; Jo, U; Kim, SH; Murai, Y; Pommier, Y; Rajapakse, VN; Saha, LK; Schultz, CW; Senatorov, IS; Takahashi, N; Thomas, A; Zenke, FT; Zimmermann, A	1
Gu, X; Liu, X; Xu, M; Zeng, T; Zhang, W; Zhang, X; Zhao, F	1
Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K	1
Alqahtani, S; Ashby, CR; Bates, SE; Chen, ZS; Deng, T; Gupta, P; Kaddoumi, A; Lei, YX; Wang, YJ; Wurpel, JND; Zhang, GN; Zhang, YK	1
Belinsky, SA; Burke, M; Dubose, D; Gigliotti, AP; Grimes, MJ; Kuehl, PJ; Revelli, DA; Tessema, M	1
An, T; Bai, H; Chen, H; Duan, J; Liu, X; Lv, C; Wang, J; Wang, Y; Wang, Z; Wu, M; Yang, X; Zhao, J; Zheng, Q; Zhong, J; Zhuo, M	1
Imai, H; Kaburagi, T; Kaira, K; Kanazawa, K; Kasai, T; Kotake, M; Minato, K; Minemura, H; Nakamura, Y; Shibata, Y; Sugiyama, T; Yamada, Y	1
Beaumont, H; Chadjaa, M; Evans, TL; Guermazi, A; Hong, SR; Klifa, C; Monostori, Z	1
Nazha, B; Owonikoko, TK	1
Kaledin, VI; Koldysheva, EV; Lavrik, OI; Lushnikova, EL; Luzina, OA; Men'shchikova, AP; Nikolin, VP; Popova, NA; Salakhutdinov, NF; Zakharenko, AL	1
Lin, B; Shao, L; Song, Z; Zhang, Y	1
Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G	1
Agelaki, S; Bompolaki, I; Chandrinos, V; Georgoulias, V; Kalbakis, K; Kontopodis, E; Kotsakis, A; Papadimitraki, E; Stoltidis, D; Zafeiriou, Z	1
Beitinjaneh, A; Bliss, RL; Dudek, AZ; Kratzke, RA; Leach, J; Powell, SF; Tessema, M	1
Cao, B; Chen, XJ; Ge, XH; Li, ZG; Lin, Q; Liu, ML; Liu, YE; Ren, XC; Wang, DY; Wang, YQ	1
Bonfill Cosp, X; Cortés-Jofré, M; Pelayo Alvarez, M; Westeel, V	1
Aisner, J; Axelrod, RS; Dahlberg, SE; Gounder, M; Owonikoko, TK; Ramalingam, SS; Rausch, PG; Rubin, EH; Schiller, JH; Wang, XV	1
Hamilton, G	1
Ardizzoni, A; Boni, L; Tiseo, M	1
Allen, JW; Gadgeel, SM; Gandara, DR; Jahanzeb, M; Kelly, K; Mack, PC; Mohamed, MK; Moon, J; Redman, M; Saba, HM	1
Ardizzoni, A; Boni, L; Buti, S; Mattioni, R; Tiseo, M	1
Ausch, C; Bajna, E; Brenner, S; Buxhofer-Ausch, V; Hamilton, G; Jäger, W; Klameth, L; Reiner, A; Riha, J; Schölm, M; Thalhammer, T	1
Adiguzel, R; Andreana, PR; Arslan, Z; Ates, M; Bemis, T; Bercovitch, LG; Bögli, S; Boucherez, J; Boudouf, S; Briat, JF; Brown, BM; Busemann, A; Buters, J; Byers, JS; Cairo, MS; Carrier, F; Chalmers, JJ; Chang, E; Chen, J; Chen, Y; Christenson, MK; Cielecka-Piontek, J; Cole, PA; Cooper, BS; Davis, PH; De Silva, RA; Decato, S; DeFries, RS; Demir, V; Denic, A; Deserno, M; Dickey, AM; Diss, E; Eberlein, B; Eyerich, S; Faluvegi, G; Farlow, MR; Fletcher, JW; Francetic, T; Furlan, L; Garbacki, P; Gartung, A; Garvin, JH; Gates, L; Gaymard, F; Ghetti, B; Gibson, MP; Griffin, RG; Hamed, M; Hammad, LA; Hammond, GB; Han, J; Hann, R; Hao, N; Harrison, LA; Heidecke, CD; Hutchins, GD; Inlow, M; Irmer, H; Jani, P; Jara-Cavieres, A; Jawadi, H; Jiang, Q; Jiang, Y; Kameda, T; Keeler, EG; Kim, H; Kim, R; Kim, S; Kinney, PL; Krause, A; Kumar, V; Kwok, Y; Lam, T; Lanni, F; Le May, M; Lee, A; Lee, JF; Lee, MJ; Leontyev, IV; Li, Q; Li, X; Liu, J; Liu, NK; Lominadze, D; Lösche, M; Lu, QB; Lu, Y; Lu, Z; Mach, H; Madsen, E; Marletta, M; Marlier, ME; McDonald, BC; McKay, IS; Mckenzie, CL; Mecozzi, S; Menges, P; Meyers, D; Michaelis, VK; Montooth, KL; Moore, LR; Morgan, JK; Morris, E; Movahed, M; Nalabothula, N; Narayanan, S; Nguyen, D; Nho, K; Oken, B; Ong, TC; Osborne, LS; Paczkowska, M; Park, EK; Pennino, D; Peters, S; Potluri, LP; Qin, C; Radhakrishnan, K; Randerson, JT; Rantanen, J; Reyt, G; Ring, J; Risacher, SL; Rodriguez, M; Saykin, AJ; Schmidt-Weber, CB; Sengelaub, DR; Shatters, RG; Shen, L; Shen, V; Shindell, DT; Stuchebrukhov, AA; Swaminathan, S; Takahashi, K; Talaczyńska, A; Tallman, EF; Tan, C; Terry, SF; Trabbic, KR; Trease, AJ; Tretter, C; Uitto, J; Váradi, A; von Bernstorff, W; Voulgarakis, A; Wagenhofer, M; Wahbeh, H; Wang, EN; Wang, X; Wells, RJ; West, JD; Williams, PS; Wolff, JE; Wootla, B; Xu, B; Xu, XM; Yoder, KK; Zalewski, P; Zan, GH; Zborowski, M; Zhang, HH; Zhang, W; Zhao, J; Zoecklein, L	1
Bosquée, L; Bubis, J; Clingan, P; Domine, M; Jotte, R; Li, S; Lorigan, P; Mezger, J; Nackaerts, K; O'Brien, ME; Reck, M; Renschler, MF; Schütte, W; Shepherd, FA; Socinski, MA; Spigel, DR; Steins, M; Trigo, JM; von Pawel, J	1
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ	1
Arya, N; Katti, DS	1
Bongiovanni, A; Burgio, MA; Califano, R; Carloni, F; Casanova, C; Cavallo, G; Di Battista, M; Genestreti, G; Kazushige, W; Kenmotsu, H; Korkmaz, T; Metro, G; Roopa, K; Scarpi, E; Selcuk, S; Tiseo, M	1
Fu, L; Lin, G; Poon, DC; To, KK; Wang, F; Wei, Y	1
Bianco, V; Francini, E; Ghiribelli, C; Laera, L; Luzzi, L; Martellucci, I; Paladini, P; Petrioli, R; Roviello, G; Voltolini, L	1
Chadjaa, M; Cho, BC; Evans, TL; Fischer, JR; Martinez, P; Ramlau, R; Shen, L; Shepherd, FA; Syrigos, KN; Udud, K; Wolf, M	1
Gjerset, RA; Zhao, M	1
Allen, J; Gandara, DR; Gitlitz, B; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ	1
Fujimoto, D; Ito, J; Katakami, N; Kato, R; Kogo, M; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Sato, Y; Shimizu, R; Teraoka, S; Tomii, K	1
Horita, N; Ikeda, M; Kaneko, T; Kobayashi, N; Kudo, M; Nagai, K; Nagakura, H; Nakashima, K; Sato, T; Shibata, Y; Shinkai, M; Tashiro, K; Tsukahara, T; Ushio, R; Watanabe, H; Yamamoto, M	1
Casaluce, F; Gridelli, C; Maione, P; Palazzolo, G; Rossi, A; Sacco, PC; Santabarbara, G; Sgambato, A	1
Bi, N; Chen, D; Feng, Q; Hui, Z; Ji, Z; Liang, J; Liu, L; Lyu, J; Wang, J; Wang, L; Wang, X; Xiao, Z; Yin, W; Zhang, H; Zhou, Z	1
Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N	1
Bessho, A; Fujimoto, N; Fujiwara, K; Harita, S; Hosokawa, S; Hotta, K; Kamei, H; Kanazawa, S; Kiura, K; Kozuki, T; Kubo, T; Kuyama, S; Maeda, T; Ninomiya, K; Ninomiya, T; Okada, T; Tabata, M; Takemoto, M; Takigawa, N; Tanimoto, M; Ueoka, H	1
Congur, G; Er, O; Erdem, A; Lambrecht, FY; Top, M	1
Horie, M; Nagase, T; Ohshima, M; Saito, A; Suzuki, HI	1
Alistar, A; Bonomi, M; Chan, MD; Isom, S; Lamar, ZS; Lycan, TW; Miller, AA; Pardee, TS; Petty, WJ; Ruiz, J	1
Barton, J; Burris, HA; Greco, FA; Infante, J; Jones, S; Patton, J; Shipley, D; Spigel, D; Thompson, D	1
Jensen, BB; Jensen, PB; Jeppesen, N; Langer, SW; Lassen, U; Mellemgaard, A; Rytter, C; Sorensen, M; Østerlind, K	1
Ross, HJ; Seung, SK	1
Friedrichs, N; Gorschlüter, M; Gressner, O; Mey, U; Popp, H; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J	1
Antras, L; Chen, L; Duh, MS; Neary, M; O'Brien, ME	1
Gomi, K; Hommura, F; Inage, M; Inoue, A; Inoue, C; Ishimoto, O; Maemondo, M; Nukiwa, T; Saijo, Y; Sugawara, S; Suzuki, T; Takanashi, S; Tsukamoto, T; Watanabe, H; Yamazaki, K; Yokouchi, H	1
Fietkau, R; Grabenbauer, GG; Hedde, JP; Ko, Y; Kocher, M; Muller, RP; Neuhaus, T; Schueller, H; Stier, S	1
Hann, CL; Rudin, CM	1
Choi, YJ; Jang, WS; Kim, CH; Lee, JC; Lee, SJ; Lee, SS; Rho, JK	1
Guo, C; Guo, QS; Liu, XJ; Liu, YL; Song, XR; Zhang, Q	1
Kakavelas, P; Kontakiotis, T; Lithoxopoulou, H; Mylonaki, E; Rapti, E; Tsiouda, T; Zarogoulidis, K; Zarogoulidis, P; Zarogoulidou, V	1
Fukuoka, M; Kashii, T; Kobayashi, M; Kurata, T; Nakagawa, K; Satoh, T; Seki, N; Takeda, K; Tsuboi, M	1
Araújo, AM; Bravo, EM; Coelho, AL; Faria, AL; Rocha, IM; Rocha, MA	1
Ji, W; Lü, JM; Ou, GF; Ren, H; Wang, LH; Wang, XZ; Yin, WB; Zhou, ZM	1
Fennell, DA; Hurwitz, JL; McCoy, F; Scullin, P	1
Arvelo, F; Assayag, F; Bourgeois, Y; Daniel, C; Decaudin, D; Froget, B; Legrier, ME; Livartowski, A; Némati, F; Poupon, MF	1
Bruzzese, F; Budillon, A; Castelli, S; Desideri, A; Di Gennaro, E; Rocco, M	1
Adjei, AA; Bryce, AH; Hillman, SL; Jett, JR; Kugler, JW; Mattar, B; Perez, EA; Rowland, K; Soori, G; Wender, DB	1
Anagnostopoulos, A; Antoniou, D; Ardavanis, A; Athanasiadis, A; Koutantos, J; Papadopoulos, G; Papakotoulas, P; Pectasides, D; Stathopoulos, GP; Trafalis, D; Vaslamatzis, M	1
Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L	1
Bird, A; Clegg, A; Harris, P; Hartwell, D; Jones, J; Loveman, E; Welch, K	1
Biernacka, B; Buczkowski, J; Krawczyk, P; Milanowski, J; Perzyło, K; Siwiec, A	1
Berros, JP; Blay, P; Coto, PP; Estrada, E; Fernandez, Y; Fra, J; Gonzalez, EE; Izquierdo, M; Jimenez, P; Lacave, AJ; Luque, M; Muñiz, I; Muriel, C; Sanmamed, M; Vieitez, JM; Villanueva, N	1
Burris, HA; Clark, BL; Gandhi, JG; Gian, VG; Greco, FA; Hainsworth, JD; Jones, SF; Peyton, JD; Spigel, DR; Vazquez, ER; West-Osterfield, K	1
Berzinec, P; Brincat, S; Kasan, P; Ostoros, G; Pesek, M; Pirker, R; Plāte, S; Purkalne, G; Rooneem, R; Skricková, J; Stanculeanu, D; Timcheva, C; Tzekova, V; Zakotnik, B; Zielinski, CC; Zwitter, M	1
Arase, H; Fukuoka, M; Ijima, T; Kudoh, S; Masuda, N; Matsui, K; Mukaiyama, A; Nakagawa, K; Negoro, S; Takada, M; Takeda, K; Yoshida, P	1
Jiang, W; Lin, L; Xu, G; Xue, C; Zhang, L; Zhang, Y; Zhao, H; Zhao, Y	1
Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Baka, S; Georgoulias, V; Gerogianni, A; Kalbakis, K; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Pavlakou, G; Tsaroucha, E; Vamvakas, L; Veslemes, M	1
Bird, A; Clegg, A; Harris, P; Hartwell, D; Jones, J; Loveman, E	1
Bashir, Z; Gooch, CL; Kleijnen, J; Riemsma, R; Simons, JP	1
Brainerd, V; Chinnasami, B; Fain, J; Fidias, P; Heist, RS; Khan, W; Leopold, L; Lynch, TJ; Molina, JR; Sequist, LV; Temel, JS	1
Zwitter, M	1
Ando, M; Ichinose, Y; Kiura, K; Nishiwaki, Y; Sakai, H; Segawa, Y; Seto, T; Watanabe, K; Yokoyama, A	1
Aglione, S; Bareggi, C; Blackhall, F; Califano, R; Collovà, E; Farina, G; Fatigoni, S; Galetta, D; Gallerani, E; Garassino, MC; Ghidini, A; La Verde, N; Lo Dico, M; Lorigan, P; Mancuso, A; Martelli, O; Michetti, G; Rossi, A; Saggia, C; Thatcher, N; Torri, V	1
Conkling, P; Fitzgibbons, JF; Galsky, MD; Jotte, R; Klein, L; McNally, R; Oliver, JW; Renschler, MF; Reynolds, C	1
Chikamori, K; Harita, S; Hosokawa, S; Hotta, K; Kishino, D; Kiura, K; Kuyama, S; Nogami, N; Shibayama, T; Shinkai, T; Tabata, M; Takigawa, N; Tamaoki, A; Tanimoto, M; Ueoka, H	1
Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Pietanza, MC; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L	1
Arrowsmith, ER; Burris, HA; Clark, BL; Greco, FA; Hainsworth, JD; Shipley, DL; Spigel, DR; Whorf, RC	1
Carloni, F; Castellani, C; Drudi, F; Lazzari-Agli, L; Sartori, S; Scarpi, E; Tassinari, D; Tombesi, P	1
Ding, Y; Li, DD; Peng, RQ; Wang, Y; Wu, XQ; Zeng, YX; Zhang, XS; Zhu, XF	1
Ando, M; Eguchi, K; Hosomi, Y; Ichinose, Y; Kiura, K; Kudo, S; Masuda, N; Matsui, K; Niho, S; Sakai, H; Shibuya, M; Takeda, K; Watanabe, K	1
Belinsky, SA; Bernauer, AM; Dacic, S; Dahlberg, SE; Klinge, DM; Liu, Y; Schiller, JH; Siegfried, JM; Tessema, M; Thomas, CL; Yingling, CM	1
Higashiguchi, M; Hirashima, T; Kawase, I; Kobayashi, M; Matsuura, Y; Morishita, N; Okamoto, N; Sasada, S; Suzuki, H; Tamiya, M; Tsumori, T; Uehara, N	1
Cui, J; Li, C; Wang, C; Wei, N; Yang, H; Zhao, X	1
Alizon, C; Hureaux, J; Urban, T	1
Maxwell, PJ; Pineda, D	1
Cardona, AF; Reveiz, L; Rueda, JR	1
Cufer, T; Kern, I; Knez, L; Ovčariček, T; Sadikov, A; Sodja, E	1
Acker, T; Banik, N; Bogenrieder, T; Eberhardt, F; Eschbach, C; Fink, TH; Heigener, DF; Huber, RM; Hummler, S; Ittel, T; Schroeder, M; Schweisfurth, H; Steinhauer, EU; Virchow, JC; Waller, C; Wolf, M	1
Alici, S; Altinbas, M; Arpaci, E; Camci, C; Gumus, M; Kalender, ME; Kaplan, MA; Karaca, H; Oven, B; Sevinc, A; Uncu, D; Yildiz, R	1
Spigel, DR	1
Jones, D; Schroeder, T; Verschraegen, C	1
Du, P; Gui, L; Han, X; Li, N; Shi, Y; Song, Y; Yang, J	1
Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N	1
Bhatt, K; Lane, S; Legenne, P; Spigel, DR; Waterhouse, DM	1
Deppermann, M; Kaubitsch, S; Keppler, U; Korfel, A; Oehm, C; Thiel, E; von Pawel, J	1
Rowinsky, EK	1
Barnes, BC; Brierre, JE; Buller, EJ; Cole, JL; Felicia Fontenot, M; Lormand, NA; Mills, G; Rainey, JM; Rinaldi, DA; Yadlapati, S	1
Chak, K; Chan, AT; Johnson, P; Lee, TW; Leung, TW; Mok, TS; Wong, H; Yeo, W; Yim, A; Yu, KH; Zee, B	1
Agelidou, M; Ferdoutsis, E; Georgoulias, V; Kalbakis, K; Kouroussis, Ch; Magkanas, E; Mavroudis, D; Samonis, G; Souglakos, J; Toumbis, M; Tselepatiotis, E; Tzanakis, N; Veslemes, M; Ziotopoulos, P	1
Beriwal, S; Garcia-Young, JA; Singh, S	1
Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L	1
Ash-Bernal, R; Browner, I; Erlich, R	1
Biggs, DD; Grubbs, SS; Guarino, MJ; Himelstein, AL; Hogaboom, K; Schneider, CJ; Tilak, S	1
Agelaki, S; Androulakis, N; Apostolopoulou, F; Blazoyiannakis, G; Georgoulias, V; Kakolyris, S; Kouroussis, Ch; Magkanas, E; Mavroudis, D; Pavlakou, G; Samonis, G; Vardakis, N; Veslemes, M	1
Ardizzoni, A; Bosquee, L; Buchholz, E; Debruyne, C; Gaafar, R; King, K; Legrand, C; Lianes, P; Manegold, C; Neumaier, C; Smit, EF; ten Velde, G	1
Asmar, L; Garfield, DH; Gregurich, MA; Joppert, MG; Khandelwal, P; Marsland, TA; Nemunaitis, JJ	1
Birch, R; Campos, L; Hainsworth, J; Schnell, F; Tongol, J; West, W	1
Sandler, AB	1
Bauman, MD; Hatfield, AK; Hillman, S; Jett, JR; Kugler, JW; Levitt, R; Mailliard, JA; Marks, RS; Morton, RF	1
Chiappori, A; Rocha Lima, CM	1
Han, M; Li, FG; Liu, ZD; Ruan, JZ; Yan, DJ; Yang, S; Yu, DP; Zhang, Y; Zhao, LQ; Zhi, XY	1
Coldman, BJ; Fossella, FV; Glisson, BS; Komaki, R; Kurie, JM; Lee, JS; Lu, C; Palmer, JL; Pisters, KM; Shin, DM	1
Bauman, MD; Ebbert, LP; Kugler, JW; Mahoney, MR; Mailliard, JA; Marks, RS; Schaefer, PL; Sloan, JA; Tazelaar, HD; Wiesenfeld, M	1
Doi, S; Kamihira, S; Kawabata, S; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Sugahara, K; Tsurutani, J; Yamada, Y	1
Baselga, J; Carrato, A; Domine, M; Felip, E; Font, A; Garrido, P; Mañe, JM; Rosell, R; Santomé, L; Terrasa, J; Vadell, C	1
Cantor, R; Dabrow, MB; Francesco, MR; Gilman, PB; Meyer, TJ; Rose, L	1
von Pawel, J	1
Greco, FA	1
Dowlati, A; Levitan, N	1
Eckardt, J	1
Treat, J	1
Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL	1
Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M	1
Beaulieu, N; Blum, K; Byrd, B; Davies, M; Hobdy, EM; Kraut, E; Masters, G; McKeon, A; Murren, JR	1
Pan, XD; Wang, CY	1
Campling, B	1
Belani, CP; Day, R; Jacobs, SA; Jett, JR; Ramalingam, S; Zamboni, BA	1
Huang, CH; Lane, SR; Levin, J; Treat, J	1
Reddy, K	1
Christodoulou, C; Deliyiannis, F; Malamos, NA; Rigatos, SK; Skarlos, DV; Stathopoulos, GP; Stathopoulos, JG	1
Bogart, JA; Green, MR; Herndon, JE; Lee, ME; Lyss, AP; Miller, AA; Turrisi, AT; Watson, D	1
Cho, LC; Choy, H	1
Hiraoka, N; Nakayama, M; Ohno, S; Takumi, C; Yamada, R; Yoshikawa, T	1
de Cremoux, P; Decaudin, D; Fréneaux, P; Judde, JG; Livartowski, A; Nemati, F; Pouillart, P; Poupon, MF; Sastre, X; Tran-Perennou, C	1
Casas, F; Jeremic, B	1
Stewart, DJ	3
Ardizzoni, A	2
Gralla, RJ	1
Eckardt, JR	3
Barachini, S; Basolo, F; Danesi, R; Del Tacca, M; Deri, M; Giovannetti, E; Mey, V	1
Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M	1
Buchholz, E; Gatzemeier, U; Goetz, E; Groth, G; Manegold, C; Reck, M	1
Fuhr, HG; Jensen, K; Keppler, U; Mueller, C; Neubauer, A; Schröder, M; Seifart, U; Staab, HJ; Ukena, J; Wolf, M	1
Hansen, LT; Kristjansen, PE; Lund, EL	1
Burger, H; Figg, WD; Gelderblom, H; Loos, WJ; Nooter, K; Sissung, TM; Sparreboom, A; Verweij, J	1
Breton, JL; Cardenal, F; Gervais, R; Lymboura, M; Mattson, K; Preston, A; Quoix, E; Ross, G; Schramel, F; Wilson, J	1
Bafaloukos, D; Briasoulis, E; Christodoulou, C; Kalofonos, HP; Koutras, A; Makatsoris, T; Samantas, E; Skarlos, DV	1
Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC	1
Donahue, A; Faucette, S; Gillenwater, HH; Kirstein, MN; Lindley, C; McCune, JS; Moore, D; Shord, S; Socinski, MA; Stewart, CF; Zamboni, WC	1
Armstrong, DK; Lane, S; Levin, J; Poulin, R; Spriggs, D	1
Penson, RT; Seiden, MV	1
Burris, HA; Corso, SW; Erland, JB; Greco, FA; Hainsworth, JD; Joseph, G; Morrissey, LH; Spigel, DR; Spremulli, E; Thompson, DS	1
Brunetti, C; Cassano, G; Colucci, G; Galetta, D; Gebbia, V; Germano, D; Giampaglia, M; Guida, M; Izzi, G; Lorusso, V; Nettis, G; Silvestris, N; Spada, M	1
Agelidou, A; Agelidou, M; Boukovinas, J; Georgoulias, V; Gerogianni, A; Ignatiadis, M; Mavroudis, D; Nikolakopoulos, J; Pavlakou, G; Syrigos, K; Tselepatiotis, E; Veslemes, M	1
Buller, R; Crawford, J; Garst, J; Lane, S	1
Gosse, H; Huber, RM; Kleinschmidt, R; Mezger, J; Reck, M; Saal, JG; Steppert, C; Steppling, H; von Pawel, J	1
Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H	1
Dimitroulis, J; Dimou, E; Karaindros, D; Katis, C; Stathopoulos, GP; Stathopoulos, J; Tsavdaridis, D	1
Perry, MC	1
Brannon, S; Crofts, TE; Eckardt, JR; Papai, Z; Ross, G; Tomova, A; Tzekova, V; von Pawel, J; Wissel, P	1
Davies, AM; Gandara, DR	1
Abratt, RP; Dane, G; Dharan, B; Gervais, R; Grotzinger, KM; Kaukel, E; Krzakowski, M; Ramlau, R; Ross, G; Shepherd, FA; von Pawel, J	1
Fournel, P	1
Pujol, JL	1
Bernath, AM; Carroll, TJ; Foster, N; Hillman, S; Jett, JR; Lair, BS; Mailliard, JA; Molina, JR; Nikcevich, D; Tazelaar, HD	1
Dai, W; Darzynkiewicz, Z; Huang, X; Kurose, A; Tanaka, T; Traganos, F	1
Harita, S; Hotta, K; Kiura, K; Kuyama, S; Nogami, N; Segawa, Y; Shibayama, T; Shinkai, T; Tabata, M; Tada, A; Takigawa, N; Tanimoto, M; Ueoka, H	1
Abrahams, C; Caligiuri, P; Desai, AA; Hogarth, DK; Maitland, ML; Salgia, R; Wilcox, R	1
Al Omari, A; Case, D; Miller, AA; Murry, DJ	1
AFlint, JA; Ardelt, B; Coradetti, T; Darzynkiewicz, Z; Davidowitz, H; Huang, Z; Lin, X; Mandecki, W; MKopacka, WM; Wang, Z	1
Dethling, J; Fink, T; Hans, K; Koschel, G; Lorenz, R; Mueller, C; Schade-Brittinger, C; Schroeder, H; Seifart, U; Wolf, M	1
Ciuleanu, TE; Crofts, T; Cuceviá, B; Dane, GC; Juhasz, G; O'Brien, ME; Ross, GA; Shparyk, Y; Thatcher, N; Tsekov, H	1
Anderson, E; Andrews, C; Bjurstrom, T; Blackwell, S; Campagna, L; Crawford, J; Garst, J; Herndon, JE; Maravich-May, D; Padilla, K; Shafman, T	1
Garst, J	1
Chhatriwala, H; Jafri, N; Salgia, R	1
Breitfeld, PP; Chen, Z; Drachtman, R; Greffe, B; Healey, J; Krailo, M; Meyers, PA; Nachman, J; Nadel, H; Reaman, GH; Sato, JK; Seibel, NL	1
Bot, BM; Garces, YI; Jett, JR; Kozelsky, TF; Mandrekar, SJ; Martens, JM; Moore, DF; Okuno, SH; Schild, SE; Soori, GS; Wender, DB	1
Nelson, R	1
Grohe, C; Hedde, JP; Kleinschmidt, R; Ko, YD; Lange, O; Losem, C; Metzler, U; Neuhaus, T; Schmidt-Wolf, IG; Schüller, H; Stier, S	1
Aydiner, A; Camlica, H; Derin, D; Guney, N; Tas, F; Topuz, E	1
Gajra, A; Garziano, S; Kirshner, J; Neuman, N; Perry, M; Ready, N; Shah, C	1
Cheng, S; Evans, WK; Shepherd, FA; Stys-Norman, D	1
Dakhil, S; Dy, GK; Geoffroy, FJ; Jett, JR; Krewer, KD; Krook, J; Kugler, J; Kutteh, L; Mailliard, J; Maurer, M; Rowland, K; Tazelaar, H; Wender, D	1
Atkins, JN; Bearden, JD; Crowley, JJ; Dakhil, SR; Dunphy, FR; Gandara, DR; Giguere, JK; Hesketh, PJ; Kelly, K; McCoy, J; Weiss, GR	1
Ettinger, DS	2
Ardizzoni, A; Dane, G; Eckardt, JR; Papai, Z; Poulin, R; Preston, AJ; Pujol, JL; Quoix, E; Ross, G; von Pawel, J	1
Nicum, SJ; O'Brien, ME	1
Chang, J; Cheon, SH; Cho, BC; Choi, HJ; Jung, JY; Kim, JH; Kim, SK; Shin, SJ; Sohn, JH	1
Bogart, JA; Green, MR; Hodgson, LD; Miller, AA; Radford, JE; Rocha Lima, CM; Vokes, EE; Wang, XF	1
Ajlouni, M; Chapman, R; Kim, JH; Lu, M; Movsas, B; Patel, SH	1
Baggstrom, MQ; Fracasso, PM; Govindan, R; Lim, WT; Read, W	1
Bo, LD; Bottiroli, G; Casalini, P; Croce, AC; Farina, C; Favini, E; Misiano, P; Petrangolini, G; Pratesi, G; Radaelli, E; Supino, R; Tortoreto, M; Zunino, F	1
Govindan, R; Morgensztern, D; Perry, MC	1
Eckardt, J; O'Brien, M; Ramlau, R	1
Jensen, BB; Jensen, PB; Johansen, J; Langer, SW; Lassen, U; Palshof, T; Sorensen, M	1
Beldner, MA; Chaudhary, U; Garrett-Mayer, E; Green, MR; Kraft, AS; Meyer, ML; Montero, AJ; Sherman, CA	1
An, CH; Cho, EK; Choi, SJ; Jeong, SH; Kim, Y; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB	1
Carden, CP; O'Brien, ME	1
Karatapanis, S; Marinopoulos, S; Rasidakis, A; Skorda, L	1
Li, QY; Shao, JH; Xiang, Y; Yang, JZ	1
Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL	1
Jensen, PB; Sehested, M; Sorensen, M	1
Cheson, B; Christian, M; Feigal, EG; Friedman, MA; Grever, M	1
Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR	1
Kim, K	1
Green, MR	1
Elias, A; Frei, E; Kalish, L; Lynch, TJ; Posner, M; Shulman, LN; Skarin, A; Strauss, G	1
Beijnen, J; de Boer-Dennert, M; Hansen, H; Koier, I; Lund, B; Planting, A; Rosing, H; Verweij, J	1
Capranico, G; Caserini, C; Colombo, A; Marchesini, R; Perego, P; Supino, R; Tronconi, M; Zunino, F	1
Fossella, FV; Glisson, BS; Hong, WK; Huber, MH; Kane, J; Kemp, BL; Kurie, JM; Lee, JJ; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Raber, MN; Robinson, RA; Shin, DM	1
Green, MR; Lilenbaum, RC; Lynch, TJ; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL	1
DeVore, R; Glick, J; Hutson, P; Johnson, D; Kim, K; Schiller, JH; Stewart, J	1
Emami, B; Graham, MV; Harms, W; Matthews, J; Purdy, JA	1
Fossella, FV; Glisson, BS; Hong, WK; Lee, JS; Murphy, WK; Perez-Soler, R; Shin, DM	1
Baker, SD; Bowling, MK; Chen, TL; Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; Kaufmann, SH; Peereboom, D; Rowinsky, EK; Sartorius, SE	1
Cooper, JD; Dresler, CM; Emami, B; Graham, MV; Jahanzeb, M; Mortimer, JE	1
Anderson, S; Beidler, D; Belliveau, D; Burtness, BA; Cheng, YC; Fedele, J; Flynn, SD; Murren, JR; Pizzorno, G; Tocino, I; Zelterman, D	1
Christensen, IJ; Holm, B; Jensen, PB; Sehested, M; Sorensen, M	1
Heuser, A; Sauer, R	1
Ardizzoni, A; Dombernowsky, P; Gamucci, T; Giaccone, G; Hansen, H; Kaplan, S; Postmus, P; Schaefer, B; Verweij, J; Wanders, J	1
Ishii, M; Joto, N; Kuga, H; Minami, M; Mitsui, I; Tohgo, A	1
Furuse, K	1
Negoro, S	2
Burris, HA; Eckardt, JR; Raymond, E; Rodriguez, G; Rowinsky, EK; Smith, L; Von Hoff, DD; Weiss, G	1
Hickish, T; Joel, S; Mainwaring, PN; Nicolson, MC; Penson, R; Slevin, M; Smith, IE	1
Schiller, JH	3
Perez-Soler, R	1
Ghaemmaghami, M; Jett, JR	1
Adler, H; Buckley, M; Cho, J; Dar, K; Fry, D; Hochster, H; Kim, T; Liebes, L; Pease, D; Potmesil, M; Zeleniuch-Jacquotte, A	1
Bunn, PA; Kelly, K	1
Beijnen, JH; Herben, VM; Hudson, I; Schot, ME; ten Bokkel Huinink, WW	1
Carney, DN	1
Grant, SC; Kindler, HL; Krebs, JB; Kris, MG; Miller, VA; Ross, GA; Slevin, ML; Smith, IE	1
Burris, H; Fields, S; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van den Burg, ME; Verweij, J; von Hoff, DD	1
Carmichael, J; Chrysson, NG; Clark, PI; Depierre, A; Fields, SZ; Gralla, R; Kleisbauer, JP; Krebs, JB; Lane, SR; Palmer, MC; Ross, G; Schiller, JH; Shepherd, FA; Stewart, DJ; von Pawel, J	1
Apicella, A; Cartení, G; Comella, G; Comella, P; Frasci, G; Gravina, A; Guida, T; Lapenta, L; Lombardi, R; Natale, M; Nicolella, GP; Pacilio, C; Panza, N	1
Ormrod, D; Spencer, CM	1
Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P	1
Ascari, E; Brugnatelli, S; Comolli, G; Danova, M; Ferrari, S; Porta, C; Pugliese, P; Riccardi, A	1
Ferreira, CG; Giaccone, G; Peters, GJ; Pinedo, HM; Tolis, C	1
Bosse, U; Falkiewicz, B; Klinke, F; Striehn, E; Vogt, U	1
Kaubitzsch, S; Lan, J; Manegold, C; Schäfer, B; Schütte, W; Staab, HJ; von Pawel, JV	1
Chen, AY; Choy, H; Rothenberg, ML	1
Chakravarthy, A; Choy, H; Johnson, D	1
Cesano, A; Fields, SZ; Lane, SR; Poulin, R; Ross, G	1
Ferreira, CG; Giaccone, G; Kummer, AJ; Peters, GJ; Pinedo, HM; Span, SW; Tolis, C; van Lopik, T	1
Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A	1
Bengtson, EM; Rigas, JR	1
Bate, WW; Grill, JP; Hatfield, AK; Jett, JR; Knost, JA; Marschke, RF; Schaefer, PL; Sloan, JA; Weitz, JJ; Zenk, DW	1
Anderson, H; Carrington, B; Cheeseman, S; Hearn, S; Ranson, M; Ross, G; Thatcher, N; White, SC	1
Kelly, K	2
Harada, M; Imai, J; Kawaguchi, T; Kiuchi, S; Okuno, S; Sakamura, Y; Tsuda, N; Tsujihara, K; Yano, S; Yano, T	1
Fleming, GF; Janisch, L; Ratain, MJ; Ryan, CW	1
Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW	1
Cesano, A; Fields, SZ; Lane, SR; Ross, GA	1
Sandler, A	1
Hansen, HH; Herrstedt, J; Hirsch, FR; Jensen, PB; Sorensen, M	1
Fujita, N; Nakashio, A; Rokudai, S; Sato, S; Tsuruo, T	1
Eckhardt, SG; Hammond, LA; Hilsenbeck, SG; MacDonald, JR; Mangold, G; Marty, J; Rowinsky, EK; Von Hoff, DD; Weitman, S	1
Ferreira, CG; Giaccone, G; Kruyt, FA; Peters, GJ; Span, SW	1
De Cesare, M; Pratesi, G; Zunino, F	1
Bildat, S; Camlett, I; Gatzemeier, U; Lane, S; Moreau, L; Pujol, JL; Ranson, M; Richardson, G; Rivière, A; Ross, G; Steppert, C; von Pawel, J	1
Berger, NA; Berger, SJ; Dowlati, A; Gordon, NH; Gosky, DM; Hoppel, CL; Ingalls, ST; Levitan, N; Remick, SC	1
Adak, S; Cella, D; DeVore, RF; Johnson, DH; Schiller, JH	1
Dingemans, AC; Giaccone, G; Postmus, PE; Scagliotti, GV; Span, S; van Ark-Otte, J; van der Valk, P	1
Baguley, BC; Baker, M; Bootle, D; Charlton, PA; Dangerfield, W; Denny, WA; Kofler, B; Mistry, P; Okiji, S; Stewart, AJ	1
Brunetti, C; Carreca, I; Comella, G; Comella, P; DeCataldis, G; Frasci, G; Muci, D; Natale, M; Nicolella, G; Palmeri, S; Panza, N; Piantedosi, F; Russo, A	1
Chastagner, P; Kozin, SV; Taghian, A	1
Barnes, B; Brierre, J; Buller, E; Cole, J; Fontenot, F; Lormand, N; Rainey, J; Rinaldi, D	1
Burris, HA; Greco, FA; Hainsworth, JD	1
Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Palamidas, P; Raptis, A	1
Huang, CH; Treat, J	1
Clark, PI; Hannigan, K; Marshall, E; O'Neill, P; Ross, G; Smith, D	1
Bakr, M; Bauer, J; Bodmer, A; Duvoisin, B; Ketterer, N; Leyvraz, S; Perey, L; Stupp, R	1
Fields, SZ; Hearn, S; Martoni, A; Pujol, JL; Ross, G; Tumolo, S; von Pawel, J	1
Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Vamvakas, L; Vardakis, N	1
Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S	1
Feng, F; He, X; Shi, Y	1
Giaccone, G; Huisman, C; Postmus, PE; Smit, EF	1
Clark, JW; Eder, JP; Huang, KC; Kwiatkowski, D; Lynch, T; Ng, SW; Ryan, DP; Seiden, MV; Skarin, A; Supko, JG	1
Kato, Y; Saijo, N	1
Burris, HA; Gray, JR; Greco, FA; Hainsworth, JD; Houston, GA; Morrissey, LH; Prasthofer, EF; Scullin, DC	1
Huang, J; Kandel, JJ; Kim, ES; Manley, C; McCrudden, KW; Middlesworth, W; O'toole, K; Soffer, SZ; Thosani, A; Yamashiro, DJ; Yokoi, A	1
Bando, H; Sano, T; Ueda, H	1
Chen, BM; Chern, JW; Leu, YL; Prijovich, ZM; Roffler, SR	1
Ettinger, DS; Forastiere, AA; Grochow, LB; Hendricks, CB; Hurowitz, LA; Kaufmann, SH; Lubejko, BG; McGuire, WP; Rowinsky, EK; Sartorius, SE	1
Ariyoshi, Y; Sugiura, T	1

Reviews

65 review(s) available for topotecan and Lung Neoplasms

Article	Year
Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Chemotherapy, 2021, Volume: 66, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Coordination Complexes; Etoposide; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome	2021
[Small cell lung cancer-Established standards and new approaches]. Innere Medizin (Heidelberg, Germany), 2022, Volume: 63, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Topotecan	2022
Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer. Journal of comparative effectiveness research, 2023, Volume: 12, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Humans; Lung Neoplasms; Platinum; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan	2023
Chemotherapy versus best supportive care for extensive small cell lung cancer. The Cochrane database of systematic reviews, 2013, Nov-27, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Methotrexate; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan	2013
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. Scientific reports, 2016, Jan-11, Volume: 6 Topics: Anthracyclines; Antineoplastic Agents; Asian People; Humans; Japan; Lung Neoplasms; Neutropenia; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome; White People	2016
Optimal drugs for second-line treatment of patients with small-cell lung cancer. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:7 Topics: Anthracyclines; Antibodies, Monoclonal; Antineoplastic Agents; Humans; Immunotherapy; Ipilimumab; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan	2016
Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park, N.Y.), 2008, Nov-30, Volume: 22, Issue:13 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dose Fractionation, Radiation; Etoposide; Humans; Lung Neoplasms; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome	2008
New advances in the second-line treatment of small cell lung cancer. The oncologist, 2009, Volume: 14, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-bcl-2; Quality of Life; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2009
The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:19 Topics: Adult; Antineoplastic Agents; Cost-Benefit Analysis; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Topotecan	2010
Therapy of small cell lung cancer with emphasis on oral topotecan. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 70, Issue:1 Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Lung Neoplasms; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan	2010
Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer treatment reviews, 2011, Volume: 37, Issue:3 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan	2011
Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC cancer, 2010, Aug-17, Volume: 10 Topics: Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topoisomerase Inhibitors; Topotecan	2010
Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials. American journal of clinical oncology, 2012, Volume: 35, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Topotecan	2012
Chemotherapy for brain metastases from small cell lung cancer. The Cochrane database of systematic reviews, 2012, Jun-13, Issue:6 Topics: Antineoplastic Agents; Brain Neoplasms; Cisplatin; Cranial Irradiation; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Teniposide; Topotecan	2012
Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule? The oncologist, 2002, Volume: 7, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Topotecan; Treatment Outcome	2002
Chemotherapy for small cell lung cancer. Seminars in oncology, 2003, Volume: 30, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Irinotecan; Lung Neoplasms; Palliative Care; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Topotecan	2003
Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 40, Issue:3 Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Small Cell; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Survival Analysis; Topotecan	2003
Single-agent chemotherapy for non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Topotecan	2003
[Current status of camptothecin derivatives as natural antitumor agents]. Yao xue xue bao = Acta pharmaceutica Sinica, 2003, Volume: 38, Issue:9 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Structure-Activity Relationship; Topotecan; Tumor Cells, Cultured	2003
Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. The oncologist, 2004, Volume: 9, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Feasibility Studies; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Topotecan	2004
Evolving role of topotecan in treating small-cell lung cancer. Clinical lung cancer, 2004, Volume: 5, Issue:5 Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Humans; Infusions, Intravenous; Lung Neoplasms; Topotecan	2004
Topoisomerase I inhibitors in the combined-modality therapy of lung cancer. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:7 Suppl 4 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan	2004
[A case of brain metastasis of small cell lung cancer improved with nogitecan hydrochloride (topotecan) after prophylactic irradiation]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:7 Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Tomography, X-Ray Computed; Topotecan	2004
In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. International journal of cancer, 2005, Feb-20, Volume: 113, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Small Cell; Cell Proliferation; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Topotecan; Transplantation, Heterologous	2005
Topotecan in the treatment of recurrent small cell lung cancer: an update. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan	2004
Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Humans; Lung Neoplasms; Palliative Care; Quality of Life; Topotecan	2004
Emerging role of weekly topotecan in recurrent small cell lung cancer. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Administration Schedule; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan	2004
Topotecan in the first-line treatment of small cell lung cancer. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Humans; Lung Neoplasms; Topotecan	2004
Update on the role of topotecan in the treatment of non-small cell lung cancer. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Topotecan	2004
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. The oncologist, 2005, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topotecan	2005
Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. Expert opinion on drug safety, 2007, Volume: 6, Issue:1 Topics: Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2007
A review of topoisomerase inhibition in lung cancer. Cancer biology & therapy, 2006, Volume: 5, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Lung Neoplasms; Topoisomerase Inhibitors; Topotecan	2006
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials, Phase III as Topic; Etoposide; Female; Humans; Infusions, Intravenous; Lomustine; Lung Neoplasms; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ontario; Practice Guidelines as Topic; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Topotecan	2007
Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific? Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:2 Topics: Anthracyclines; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Europe; Humans; Japan; Lung Neoplasms; Topotecan; United States	2007
Topotecan for the treatment of small-cell lung cancer. Expert review of anticancer therapy, 2007, Volume: 7, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Humans; Lung Neoplasms; Topotecan	2007
Recent advances with topotecan in the treatment of lung cancer. The oncologist, 2007, Volume: 12, Issue:10 Topics: Antineoplastic Agents; Humans; Lung Neoplasms; Topotecan	2007
Camptothecin analogues in the treatment of non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 1995, Volume: 12 Suppl 1 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Topotecan	1995
New drugs for treating small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 1995, Volume: 12 Suppl 3 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan	1995
New chemotherapeutic agents in non-small-cell lung cancer. Seminars in oncology, 1993, Volume: 20, Issue:2 Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; Humans; Interferons; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine	1993
New chemotherapeutic agents for non-small cell lung cancer. Chest, 1995, Volume: 107, Issue:6 Suppl Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine	1995
New directions for chemotherapy in non-small-cell lung cancer. Chest, 1993, Volume: 103, Issue:4 Suppl Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine	1993
[Topoisomerase I inhibitor with potential radiosensitizing effect]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1997, Volume: 173, Issue:3 Topics: Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Child; Clinical Trials as Topic; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topoisomerase I Inhibitors; Topotecan	1997
[Lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine	1997
["State-of-the-art" chemotherapy for small-cell lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine	1997
Topotecan in small cell lung cancer. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 20 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Topoisomerase I Inhibitors; Topotecan	1997
Topotecan in the treatment of non-small cell lung cancer. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 20 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasm Staging; Topoisomerase I Inhibitors; Topotecan	1997
New agents in the treatment of small cell lung cancer. Chest, 1998, Volume: 113, Issue:1 Suppl Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	1998
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine	1998
New agents in the management of advanced non-small cell lung cancer. Seminars in oncology, 1998, Volume: 25, Issue:4 Suppl 9 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine	1998
Topotecan: a review of its efficacy in small cell lung cancer. Drugs, 1999, Volume: 58, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; In Vitro Techniques; Lung Neoplasms; Topotecan	1999
DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:10 Suppl 5 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan	1999
The role of radiation, with or without chemotherapy, in the management of NSCLC. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:10 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Topotecan; Vinblastine; Vinorelbine	1999
New oral chemotherapeutic agents for lung cancer. Drugs, 1999, Volume: 58 Suppl 3 Topics: Administration, Oral; Animals; Antineoplastic Agents; Bexarotene; Biphenyl Compounds; Clinical Trials as Topic; Humans; Lung Neoplasms; Organic Chemicals; Organoplatinum Compounds; Phenylbutyrates; Tetrahydronaphthalenes; Topotecan; Vinblastine; Vinorelbine	1999
New chemotherapy agents for small cell lung cancer. Chest, 2000, Volume: 117, Issue:4 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine	2000
Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients. International journal of oncology, 2000, Volume: 17, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Databases, Factual; Disease Progression; Female; Humans; Injections, Intravenous; Karnofsky Performance Status; Life Tables; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Survival Analysis; Topotecan; Treatment Outcome	2000
Extensive small-cell lung cancer: a treatment overview. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:7 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine	2000
Treatment of extensive stage small cell lung cancer. Cancer treatment and research, 2001, Volume: 105 Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	2001
Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience. Seminars in oncology, 2001, Volume: 28, Issue:2 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Etoposide; Humans; Lung Neoplasms; Paclitaxel; Topotecan	2001
New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors. Oncology, 2001, Volume: 61 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Male; Prognosis; Survival Analysis; Topotecan; Treatment Outcome	2001
Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer. Oncology, 2001, Volume: 61 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Analysis; Topotecan; Treatment Outcome	2001
Future role of topotecan in the treatment of lung cancer. Oncology, 2001, Volume: 61 Suppl 1 Topics: Administration, Oral; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Forecasting; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Survival Analysis; Topotecan; Treatment Outcome	2001
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2001, Volume: 34 Suppl 4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine	2001
[Developed new agents for lung cancer]. Nihon Geka Gakkai zasshi, 2002, Volume: 103, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine	2002
[Nogitecan hydrochloride]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 5 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan	2002
[DNA topoisomerase inhibitor]. Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:13 Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Phenazines; Topoisomerase I Inhibitors; Topotecan	1992

Trials

131 trial(s) available for topotecan and Lung Neoplasms

Article	Year
Pharmacokinetic Drug-Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer. Clinical drug investigation, 2022, Volume: 42, Issue:8 Topics: Area Under Curve; Drug Interactions; Healthy Volunteers; Humans; Itraconazole; Lung Neoplasms; Metformin; Midazolam; Prospective Studies; Pyrimidines; Pyrroles; Rifampin; Topotecan	2022
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies. The oncologist, 2023, 07-05, Volume: 28, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Genital Neoplasms, Female; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan	2023
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan. Acta oncologica (Stockholm, Sweden), 2023, Volume: 62, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Lung Neoplasms; Platinum; Small Cell Lung Carcinoma; Topotecan	2023
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021, Volume: 16, Issue:9 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Humans; Immunoconjugates; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Middle Aged; Small Cell Lung Carcinoma; Topotecan	2021
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018, Volume: 20, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2018
Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection. Cancer imaging : the official publication of the International Cancer Imaging Society, 2018, Dec-11, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Factors; Small Cell Lung Carcinoma; Taxoids; Topotecan; Tumor Burden	2018
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Palliative Care; Small Cell Lung Carcinoma; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan	2013
Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer. Clinical lung cancer, 2013, Volume: 14, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Topotecan	2013
Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer. Radiation oncology (London, England), 2013, Oct-14, Volume: 8 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Radiotherapy, Conformal; Small Cell Lung Carcinoma; Topotecan	2013
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	2014
Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Aug-10, Volume: 32, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lung Neoplasms; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Small Cell Lung Carcinoma; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Dec-10, Volume: 32, Issue:35 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Disease-Free Survival; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; NAD(P)H Dehydrogenase (Quinone); Odds Ratio; Polymorphism, Single Nucleotide; Proportional Hazards Models; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome; Young Adult	2014
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult	2015
Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Response Evaluation Criteria in Solid Tumors; Retreatment; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan	2015
Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clinical lung cancer, 2016, Volume: 17, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Databases, Factual; Female; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Outcome Assessment; Platinum Compounds; Prognosis; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Survival Analysis; Therapies, Investigational; Topotecan; Treatment Outcome; Young Adult	2016
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2016
A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Endpoint Determination; Female; Humans; Lung Neoplasms; Male; Radiotherapy; Small Cell Lung Carcinoma; Survival Analysis; Topotecan	2016
A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PloS one, 2016, Volume: 11, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Cell Line, Tumor; Female; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Sulfides; Topoisomerase I Inhibitors; Topotecan	2016
A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. Clinical lung cancer, 2008, Volume: 9, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Topotecan; Treatment Outcome	2008
Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2008
Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer. International journal of radiation oncology, biology, physics, 2009, Mar-01, Volume: 73, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Taxoids; Topotecan	2009
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-20, Volume: 26, Issue:33 Topics: Aged; Anthracyclines; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan	2008
A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. British journal of cancer, 2009, Jan-27, Volume: 100, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Quality of Life; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2009
A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Young Adult	2009
Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study. American journal of clinical oncology, 2010, Volume: 33, Issue:4 Topics: Administration, Oral; Adult; Aged; Carboplatin; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Time Factors; Topotecan; Treatment Outcome	2010
Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study. Anti-cancer drugs, 2010, Volume: 21, Issue:2 Topics: Administration, Oral; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia; Time Factors; Topotecan; Treatment Outcome	2010
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesylates; Middle Aged; Patient Selection; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Topotecan	2010
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. Investigational new drugs, 2011, Volume: 29, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Prospective Studies; Survival; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2011
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Topotecan	2010
Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer. Clinical lung cancer, 2010, Jul-01, Volume: 11, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy; Survival Rate; Tissue Distribution; Topotecan; Treatment Outcome	2010
Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. Anticancer research, 2010, Volume: 30, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2010
Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Resistance, Neoplasm; Female; Gossypol; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2010
Phase I study of topotecan and cisplatin in patients with small cell lung cancer. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Small Cell Lung Carcinoma; Topotecan	2011
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 72, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome	2011
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jan-20, Volume: 29, Issue:3 Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma; Survival Analysis; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan; United States	2011
A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:1 Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome	2011
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Thrombocytopenia; Topotecan	2011
A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer. Clinical lung cancer, 2011, Volume: 12, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan	2011
Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer research, 2011, Volume: 31, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome; Young Adult	2011
Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Small Cell Lung Carcinoma; Topotecan	2012
A phase I study of concurrent external beam radiotherapy with weekly topotecan for primary treatment of locally advanced lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:12 Topics: Adolescent; Chemoradiotherapy; Cohort Studies; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Topotecan	2012
Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS. Journal of pharmaceutical and biomedical analysis, 2013, Mar-25, Volume: 76 Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; China; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Limit of Detection; Lung Neoplasms; Male; Reproducibility of Results; Small Cell Lung Carcinoma; Tandem Mass Spectrometry; Topoisomerase I Inhibitors; Topotecan	2013
Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Clinical lung cancer, 2013, Volume: 14, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2013
Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:13 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cranial Irradiation; Disease Progression; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Prospective Studies; Survival Analysis; Topotecan	2002
A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma. Cancer, 2002, Sep-15, Volume: 95, Issue:6 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan	2002
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer, 2002, Oct-01, Volume: 95, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topotecan	2002
Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Lung cancer (Amsterdam, Netherlands), 2002, Volume: 38, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease Progression; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival; Thrombocytopenia; Topotecan; Treatment Outcome	2002
A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer. The oncologist, 2002, Volume: 7, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome	2002
Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 39, Issue:1 Topics: Adult; Aged; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Time Factors; Topotecan; Treatment Outcome	2003
European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Recurrence; Time Factors; Topotecan	2003
A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 39, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan; Treatment Outcome	2003
Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. The oncologist, 2003, Volume: 8, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Topotecan; Treatment Outcome	2003
Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group. Cancer, 2003, May-15, Volume: 97, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Illinois; Indiana; Iowa; Lung Neoplasms; Male; Middle Aged; Minnesota; Nebraska; Neoplasm Staging; North Dakota; Paclitaxel; South Dakota; Survival Analysis; Topotecan; Treatment Outcome	2003
A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan	2003
Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. American journal of clinical oncology, 2003, Volume: 26, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan; Treatment Outcome	2003
Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan	2003
Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer. Cancer investigation, 2003, Volume: 21, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis; Topotecan; Treatment Outcome	2003
A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer. Cancer biology & therapy, 2004, Volume: 3, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Survival Analysis; Survivors; Time Factors; Topotecan; Treatment Outcome	2004
Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Topotecan	2004
Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan	2004
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. International journal of radiation oncology, biology, physics, 2004, Jun-01, Volume: 59, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Small Cell Lung Carcinoma; Survival Analysis; Topotecan	2004
Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome	2005
Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung cancer (Amsterdam, Netherlands), 2005, Volume: 48, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan	2005
A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Topotecan; Treatment Outcome	2005
Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG). Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan; Treatment Outcome	2006
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. Cancer investigation, 2005, Volume: 23, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival; Topotecan; Treatment Outcome	2005
Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. The oncologist, 2005, Volume: 10, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel; Topotecan	2005
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial. Oncology reports, 2005, Volume: 14, Issue:6 Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Platinum; Thrombocytopenia; Topotecan; Treatment Outcome	2005
Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. Clinical lung cancer, 2005, Volume: 7, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Topotecan	2005
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. The European respiratory journal, 2006, Volume: 27, Issue:6 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Neutrophils; Organoplatinum Compounds; Platelet Count; Retreatment; Survival Rate; Topotecan; Treatment Outcome	2006
Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial. Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Topotecan	2006
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-01, Volume: 24, Issue:13 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Topotecan	2006
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Topotecan	2006
Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. American journal of clinical oncology, 2006, Volume: 29, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Topotecan; Treatment Outcome	2006
A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:2 Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carcinoma, Small Cell; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Treatment Outcome	2006
Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 54, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome	2006
Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Small Cell; Central Nervous System Neoplasms; Cisplatin; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Time Factors; Topotecan; Treatment Outcome	2007
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Dec-01, Volume: 24, Issue:34 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Survival Rate; Topotecan	2006
A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. Clinical drug investigation, 2006, Volume: 26, Issue:5 Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Survival Rate; Topotecan; Treatment Outcome	2006
Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943. Cancer, 2007, Apr-15, Volume: 109, Issue:8 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Female; Humans; Lung Neoplasms; Maximum Tolerated Dose; Osteosarcoma; Prognosis; Survival Analysis; Survival Rate; Topotecan	2007
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. International journal of radiation oncology, biology, physics, 2007, Mar-15, Volume: 67, Issue:4 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality Control; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topotecan	2007
A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors. International journal of radiation oncology, biology, physics, 2007, Jul-01, Volume: 68, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Topotecan; Treatment Outcome	2007
A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan; Vomiting	2007
Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Topotecan	2006
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Probability; Prognosis; Risk Factors; Survival Analysis; Topotecan	2006
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-20, Volume: 25, Issue:15 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Rate; Topotecan	2007
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Severity of Illness Index; Survival Rate; Topotecan; Treatment Outcome	2007
A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:9 Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiation-Sensitizing Agents; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	2007
A Phase I trial of weekly docetaxel and topotecan for solid tumors. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Risk Factors; Taxoids; Topotecan; Treatment Outcome	2008
A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Recombinant Proteins; Taxoids; Topotecan; Treatment Failure	2008
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial. Lung cancer (Amsterdam, Netherlands), 2008, Volume: 60, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Radiotherapy, Conformal; Topotecan	2008
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC cancer, 2007, Dec-20, Volume: 7 Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Vinblastine; Vinorelbine	2007
Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Topotecan	2008
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan	1994
Phase II study of topotecan in metastatic non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:2 Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Topotecan; Treatment Outcome	1994
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:8 Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Pancreatic Neoplasms; Remission Induction; Topoisomerase I Inhibitors; Topotecan	1993
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thrombocytopenia; Topotecan; Treatment Outcome	1996
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Sepsis; Topotecan	1996
Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; United States	1996
3-D conformal radiotherapy for lung cancer. The Washington University experience. Frontiers of radiation therapy and oncology, 1996, Volume: 29 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Feasibility Studies; Humans; Lung Neoplasms; Lymph Nodes; Missouri; Radiation Injuries; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Thorax; Topotecan	1996
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Topotecan; Tumor Cells, Cultured	1996
Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer. International journal of radiation oncology, biology, physics, 1996, Dec-01, Volume: 36, Issue:5 Topics: Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Thorax; Topotecan	1996
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Dr Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:5 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Humans; Lung Neoplasms; Remission Induction; Survival Analysis; Topotecan	1997
Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan	1997
Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. British journal of cancer, 1997, Volume: 76, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Topotecan	1997
Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:3 Topics: Adenoma, Islet Cell; Antineoplastic Agents; Autoantibodies; Autoantigens; Biomarkers; Biopsy; Breast Neoplasms; Cell Line; DNA Topoisomerases, Type I; Endometrial Neoplasms; Esophageal Neoplasms; Female; Gastrointestinal Neoplasms; HeLa Cells; Humans; Lung Neoplasms; Nuclear Proteins; Ovarian Neoplasms; Pancreatic Neoplasms; Scleroderma, Systemic; Stomach Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1998
Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. Anti-cancer drugs, 1998, Volume: 9, Issue:5 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Biomarkers; Carcinoma, Small Cell; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Thrombocytopenia; Topotecan; Treatment Outcome; Vomiting	1998
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. American journal of clinical oncology, 1998, Volume: 21, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Infusion Pumps; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:7 Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Fatigue; Female; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Topotecan; Treatment Outcome	1998
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Topotecan; Vincristine	1999
Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan; Treatment Outcome	1999
A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2000, Volume: 28, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome	2000
Phase II study of oral topotecan in advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Thrombocytopenia; Topotecan; Treatment Outcome; Vomiting	2000
A phase I study of liposomal doxorubicin (Doxil) with topotecan. American journal of clinical oncology, 2000, Volume: 23, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan	2000
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan	2000
Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-15, Volume: 19, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Neutropenia; Topotecan; Treatment Outcome	2001
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Etoposide; Female; Humans; Hypoxanthine Phosphoribosyltransferase; Lung Neoplasms; Male; Middle Aged; Mutation; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	2001
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Topotecan; Treatment Outcome	2001
A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. British journal of cancer, 2001, May-04, Volume: 84, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Topotecan	2001
A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3). Cancer investigation, 2001, Volume: 19, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan; Treatment Outcome	2001
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2001, Volume: 34, Issue:1 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topotecan	2001
A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer. Oncology, 2001, Volume: 61 Suppl 1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan; Treatment Outcome	2001
Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer. Oncology, 2001, Volume: 61 Suppl 1 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Topotecan; Treatment Outcome	2001
Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine. Oncology, 2001, Volume: 61 Suppl 1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Sensitivity and Specificity; Survival Rate; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	2001
Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy. Oncology, 2001, Volume: 61 Suppl 1 Topics: Administration, Oral; Adult; Aged; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Topotecan; Treatment Outcome	2001
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors. Oncology, 2001, Volume: 61, Issue:4 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms	2001
[Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2001, Volume: 23, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Leukopoiesis; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan; Treatment Outcome	2001
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome	2001
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:3 Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; DNA Primers; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Safety; Topotecan; Treatment Outcome	2002
Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer, 2002, May-01, Volume: 94, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Topotecan; Treatment Outcome	2002
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Topotecan	1992

Other Studies

133 other study(ies) available for topotecan and Lung Neoplasms

Article	Year
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. Journal of medicinal chemistry, 1991, Volume: 34, Issue:1 Topics: Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Line; Colonic Neoplasms; DNA, Superhelical; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Indicators and Reagents; Leukemia L1210; Lung Neoplasms; Melanoma, Experimental; Mice; Molecular Structure; Plasmids; Structure-Activity Relationship; Thymus Gland; Topoisomerase I Inhibitors; Transplantation, Heterologous	1991
Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin. Bioorganic & medicinal chemistry letters, 2001, Feb-12, Volume: 11, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Division; Combinatorial Chemistry Techniques; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Structure-Activity Relationship; Survival Rate; Tumor Cells, Cultured	2001
Synthesis and cytotoxic activity of a new series of topoisomerase I inhibitors. Bioorganic & medicinal chemistry letters, 2008, Feb-15, Volume: 18, Issue:4 Topics: Anthraquinones; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Pyrones; Structure-Activity Relationship; Topoisomerase I Inhibitors	2008
A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors. Journal of medicinal chemistry, 2013, Oct-24, Volume: 56, Issue:20 Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Drug Design; Drug Screening Assays, Antitumor; Drug Stability; Humans; Lactones; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Chemical; Molecular Structure; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays	2013
Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topoteсan on in vivo tumor models. European journal of medicinal chemistry, 2019, Jan-01, Volume: 161 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Phosphoric Diester Hydrolases; Quantum Theory; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan	2019
Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo. European journal of medicinal chemistry, 2022, Nov-05, Volume: 241 Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Lung Neoplasms; Small Cell Lung Carcinoma	2022
FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11. Acta pharmacologica Sinica, 2022, Volume: 43, Issue:8 Topics: Cell Line, Tumor; Depsipeptides; DNA Methylation; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Nuclear Proteins; Small Cell Lung Carcinoma; Topotecan	2022
Intraventricular topotecan in the successful treatment of recurrent CNS pleuropulmonary blastoma. Pediatric blood & cancer, 2022, Volume: 69, Issue:3 Topics: Central Nervous System; Child; DEAD-box RNA Helicases; Germ-Line Mutation; Humans; Lung Neoplasms; Pulmonary Blastoma; Ribonuclease III; Topotecan	2022
CDK7 Inhibition Synergizes with Topoisomerase I Inhibition in Small Cell Lung Cancer Cells by Inducing Ubiquitin-Mediated Proteolysis of RNA Polymerase II. Molecular cancer therapeutics, 2022, 09-06, Volume: 21, Issue:9 Topics: Antineoplastic Agents; Cell Line, Tumor; Cyclin-Dependent Kinases; DNA Topoisomerases, Type I; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proteolysis; RNA Polymerase II; Small Cell Lung Carcinoma; Topotecan; Ubiquitin	2022
The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells. Biochemical pharmacology, 2022, Volume: 205 Topics: Animals; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Topoisomerase Inhibitors; Topotecan	2022
Novel treatment of refractory / recurrent pulmonary hepatoblastoma. Pediatrics international : official journal of the Japan Pediatric Society, 2020, Volume: 62, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Female; Hepatoblastoma; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Oxaliplatin; Radiofrequency Ablation; Retrospective Studies; Survival Rate; Topotecan; Treatment Outcome; Vincristine	2020
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer. European journal of cancer care, 2020, Volume: 29, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Comorbidity; Cyclophosphamide; Deprescriptions; Docetaxel; Doxorubicin; Drug Tapering; Etoposide; Female; Functional Status; Humans; Lung Neoplasms; Male; Middle Aged; Netherlands; Paclitaxel; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2020
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung cancer (Amsterdam, Netherlands), 2020, Volume: 146 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan	2020
Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes. Current drug metabolism, 2020, Volume: 21, Issue:11 Topics: A549 Cells; Administration, Intravenous; Animals; Cell Survival; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Liposomes; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Polyethylene Glycols; Rats, Sprague-Dawley; Topoisomerase I Inhibitors; Topotecan	2020
Carboplatin plus etoposide or topotecan for small-cell lung cancer. The Lancet. Oncology, 2020, Volume: 21, Issue:9 Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan	2020
[New European approvals: Durvalumab - In first line metastatic small-cell lung cancer]. Bulletin du cancer, 2020, Volume: 107, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Immunotherapy; Lung Neoplasms; Nivolumab; Small Cell Lung Carcinoma; Topotecan	2020
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer. The Lancet. Oncology, 2020, Volume: 21, Issue:12 Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan	2020
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer - Authors' reply. The Lancet. Oncology, 2020, Volume: 21, Issue:12 Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan	2020
A rational targeted therapy for platinum-resistant small-cell lung cancer. Cancer cell, 2021, 04-12, Volume: 39, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Platinum; Topotecan	2021
Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. Drug delivery, 2021, Volume: 28, Issue:1 Topics: Administration, Inhalation; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemistry, Pharmaceutical; Genes, erbB-1; Half-Life; Humans; Lung Neoplasms; Metabolic Clearance Rate; Proto-Oncogene Proteins p21(ras); Rats; Rats, Sprague-Dawley; Topoisomerase I Inhibitors; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays	2021
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents. Molecular cancer therapeutics, 2021, Volume: 20, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Deoxycytidine; DNA Replication; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Isoxazoles; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Pyrazines; Pyrazoles; Small Cell Lung Carcinoma; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2021
Autophagy inhibition and microRNA‑199a‑5p upregulation in paclitaxel‑resistant A549/T lung cancer cells. Oncology reports, 2021, Volume: 46, Issue:1 Topics: A549 Cells; Autophagy; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; MicroRNAs; Oxaliplatin; Paclitaxel; Sequestosome-1 Protein; Topotecan; Up-Regulation; Vinorelbine	2021
Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo. Cancer letters, 2018, 06-28, Volume: 424 Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Neoplasm Proteins; Quinazolines; Topotecan; Up-Regulation; Xenograft Model Antitumor Assays	2018
Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model. Drug delivery, 2018, Volume: 25, Issue:1 Topics: A549 Cells; Administration, Inhalation; Administration, Intravenous; Animals; Dry Powder Inhalers; Humans; Lung; Lung Neoplasms; Male; Particle Size; Powders; Rats; Rats, Nude; Topotecan	2018
Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. Thoracic cancer, 2018, Volume: 9, Issue:9 Topics: Aged; Biomarkers, Tumor; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Recurrence; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Topoisomerase I Inhibitors; Topotecan	2018
Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. Thoracic cancer, 2018, Volume: 9, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Recurrence; Retreatment; Retrospective Studies; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2018
The clinical conundrum of managing relapsed small cell lung cancer. Cancer, 2019, 04-01, Volume: 125, Issue:7 Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan	2019
Antimetastatic Activity of Combined Topotecan and Tyrosyl-DNA Phosphodiesterase-1 Inhibitor on Modeled Lewis Lung Carcinoma. Bulletin of experimental biology and medicine, 2019, Volume: 166, Issue:5 Topics: Animals; Carcinoma, Lewis Lung; Enzyme Inhibitors; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Phosphoric Diester Hydrolases; Topotecan	2019
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan	2013
[Analysis of drug therapy of lung cancer in Hungary]. Magyar onkologia, 2013, Volume: 57, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan	2013
Cytotoxic effects of fascaplysin against small cell lung cancer cell lines. Marine drugs, 2014, Mar-07, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cell Cycle; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 4; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Indoles; Lung Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Porifera; Reactive Oxygen Species; Topotecan	2014
Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:13 Topics: Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Small Cell Lung Carcinoma; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	2014
Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 86, Issue:1 Topics: Aged; Antineoplastic Agents; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2014
Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy. Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; Chromogranins; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lung; Lung Neoplasms; Organic Anion Transporters; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Synaptophysin; Topotecan; Tumor Cells, Cultured	2015
Bulletin of the World Health Organization, 2014, Nov-01, Volume: 92, Issue:11 Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude of Health Personnel; Carboplatin; Child; Child, Preschool; Curriculum; Databases, Factual; Education, Medical; Enzyme Inhibitors; Etoposide; Europe; Female; General Surgery; Germany; Hospitals, University; Humans; Ifosfamide; Lung Neoplasms; Male; Medical History Taking; Mesothelioma; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Neurons; Muscular Atrophy; Neoplasms; Neuroprotective Agents; Phospholipase A2 Inhibitors; Phospholipases A2, Cytosolic; Physical Examination; Quality Improvement; Spinal Cord Injuries; Topotecan; Universities; World Health Organization; Young Adult	2014
Poly(d,l-lactide-co-glycolide)-chitosan composite particles for the treatment of lung cancer. International journal of nanomedicine, 2015, Volume: 10 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitosan; Drug Carriers; Drug Synergism; Humans; Lactic Acid; Lung Neoplasms; Nanocomposites; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Topotecan	2015
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. Clinical lung cancer, 2015, Volume: 16, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum Compounds; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome	2015
Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer. British journal of pharmacology, 2015, Volume: 172, Issue:16 Topics: Adenosine Triphosphatases; Aminoquinolines; Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Hyperthermia, Induced; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Topotecan; Up-Regulation	2015
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience. Clinical lung cancer, 2015, Volume: 16, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Etoposide; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Neutropenia; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome	2015
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker. PloS one, 2015, Volume: 10, Issue:8 Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan	2015
Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease. Anticancer research, 2015, Volume: 35, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2015
[Outcome of concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cyclophosphamide; Esophagitis; Humans; Lung Neoplasms; Neoplasm Staging; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Topotecan	2015
Intracellular uptake study of radiolabeled anticancer drug and impedimetric detection of its interaction with DNA. Talanta, 2016, Nov-01, Volume: 160 Topics: A549 Cells; Antineoplastic Agents; Biological Transport; Cell Line; Cell Survival; Dielectric Spectroscopy; DNA; Humans; Iodine Radioisotopes; Lung Neoplasms; Topotecan	2016
YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer. Cancer science, 2016, Volume: 107, Issue:12 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Lung Neoplasms; Phenotype; Phosphoproteins; Small Cell Lung Carcinoma; Topotecan; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Transcriptome; YAP-Signaling Proteins	2016
Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation. Onkologie, 2008, Volume: 31, Issue:8-9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome	2008
Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Palliative Care; Randomized Controlled Trials as Topic; Self-Assessment; Severity of Illness Index; Sickness Impact Profile; Small Cell Lung Carcinoma; Surveys and Questionnaires; Topotecan	2008
HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines. Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:8 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	2009
[Down-regulation of TopI by RNA interference reduces the drug-sensitivity of small cell lung cancer cell lines to topotecan]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:10 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Down-Regulation; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Small Cell Lung Carcinoma; Topotecan; Transfection	2008
Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2009, Volume: 66, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Tolerance; Etoposide; Female; Humans; Lung Neoplasms; Male; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome	2009
Topotecan in second-line treatment of small-cell lung cancer--how it works in our daily clinical practice? Current drug safety, 2010, Volume: 5, Issue:2 Topics: Adult; Aged; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2010
[Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Topotecan	2009
Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts. Anti-cancer drugs, 2010, Volume: 21, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Humans; Ifosfamide; Lung Neoplasms; Mice; Mice, Nude; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome; Xenograft Model Antitumor Assays	2010
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Molecular cancer therapeutics, 2009, Volume: 8, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; DNA Damage; DNA Topoisomerases, Type I; Drug Synergism; Histone Deacetylases; Humans; Hydroxamic Acids; Lung Neoplasms; Reactive Oxygen Species; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan; Vorinostat	2009
[Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report]. Pneumonologia i alergologia polska, 2010, Volume: 78, Issue:3 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Poland; Proportional Hazards Models; Recurrence; Survival Analysis; Topotecan; Treatment Outcome	2010
[Immediate versus delayed topotecan after first-line therapy in small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2010, Volume: 13, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Topotecan; Treatment Outcome	2010
Combining cytotoxic and targeted therapies for lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Gossypol; Humans; Lung Neoplasms; Topotecan	2010
Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells. Chinese journal of cancer, 2011, Volume: 30, Issue:10 Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Cell Line, Tumor; Cell Proliferation; Chloroquine; Drug Synergism; Humans; Lung Neoplasms; Membrane Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Topoisomerase I Inhibitors; Topotecan	2011
SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene, 2012, Sep-13, Volume: 31, Issue:37 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Cytokines; DNA Methylation; DNA Topoisomerases, Type I; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Sulfatases; Sulfotransferases; Topoisomerase I Inhibitors; Topotecan; Ubiquitins	2012
Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease. Journal of chemotherapy (Florence, Italy), 2011, Volume: 23, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Topotecan	2011
Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity. The Journal of pharmacy and pharmacology, 2012, Volume: 64, Issue:3 Topics: Ammonium Sulfate; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Carcinoma, Lewis Lung; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Half-Life; Hand-Foot Syndrome; Humans; Injections, Intravenous; Leukemia L1210; Liposomes; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasms; Phosphatidylethanolamines; Polyethylene Glycols; Prostatic Neoplasms; Random Allocation; Rats; Rats, Wistar; Skin; Skin Diseases; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan	2012
[Postmarketing surveillance study on the use of topotecan in small-cell lung cancer. Use of topotecan in a pneumology university department]. Revue des maladies respiratoires, 2012, Volume: 29, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hospital Departments; Hospitals, University; Humans; Lung Neoplasms; Male; Middle Aged; Product Surveillance, Postmarketing; Pulmonary Medicine; Small Cell Lung Carcinoma; Topotecan; Young Adult	2012
Small cell lung cancer metastasizing to the colon in a colovesicular fistula in the setting of diverticulitis. The American surgeon, 2012, Volume: 78, Issue:5 Topics: Aged, 80 and over; Biopsy, Needle; Colectomy; Colostomy; Combined Modality Therapy; Diverticulitis, Colonic; Female; Follow-Up Studies; Humans; Immunohistochemistry; Intestinal Fistula; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Radiotherapy Dosage; Risk Assessment; Sigmoid Neoplasms; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Topotecan; Treatment Outcome; Urinary Bladder Fistula	2012
Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:18 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Epirubicin; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pilot Projects; Prognosis; Retrospective Studies; Single-Blind Method; Slovenia; Topotecan; Treatment Outcome; Vincristine	2012
Weekly topotecan for recurrent small cell lung cancer - a retrospective Anatolian Medical Oncology Group study. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:6 Topics: Adult; Aged; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2012
Treatment update in small-cell lung cancer: from limited to extensive disease. Current treatment options in oncology, 2012, Volume: 13, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Topotecan	2012
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. American journal of clinical oncology, 2015, Volume: 38, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome	2015
Tumor lysis syndrome in extensive-stage small-cell lung cancer. American journal of clinical oncology, 2002, Volume: 25, Issue:5 Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Small Cell; Enzyme Inhibitors; Fatal Outcome; Female; Humans; Lung Neoplasms; Topotecan; Tumor Lysis Syndrome	2002
Unexpected pleural effusions in 3 pediatric patients treated with STI-571. Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:8 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan	2002
Early detection and successful treatment of drug-induced pneumonitis with corticosteroids. Cancer investigation, 2002, Volume: 20, Issue:7-8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Paclitaxel; Pneumonia; Prednisone; Radiography, Thoracic; Tomography, X-Ray Computed; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine	2002
[Second-line Hycamtin in the treatment of lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2003, Volume: 25, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Male; Middle Aged; Topotecan	2003
Expression and functional analyses of breast cancer resistance protein in lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Transport; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan	2003
The role of topotecan in treating small cell lung cancer: second-line treatment. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4 Topics: Administration, Oral; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Lung Neoplasms; Topoisomerase I Inhibitors; Topotecan	2003
Topotecan as first-line therapy for small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell; Cisplatin; Etoposide; Forecasting; Humans; Lung Neoplasms; Paclitaxel; Platinum; Topotecan	2003
Combination chemotherapy with topotecan for non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Vinblastine; Vinorelbine	2003
Weekly topotecan in the management of lung cancer. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 41 Suppl 4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Administration Schedule; Humans; Lung Neoplasms; Topotecan	2003
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics. British journal of cancer, 2003, Nov-03, Volume: 89, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured	2003
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. International journal of cancer, 2004, Jan-01, Volume: 108, Issue:1 Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Coumarins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Novobiocin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	2004
Topotecan in small cell lung cancer: first or second line? Cancer biology & therapy, 2004, Volume: 3, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Reproducibility of Results; Topotecan	2004
In regard to Bogart et al.: 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage non-small-cell lung cancer: Analysis of cancer and leukemia group B study 39808 (Int J Radiat Oncol Biol Phys 2004;59:460-468). International journal of radiation oncology, biology, physics, 2004, Dec-01, Volume: 60, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage; Recurrence; Topotecan	2004
Foreword--new directions for topotecan in lung cancer treatment. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Humans; Lung Neoplasms; Quality of Life; Topotecan	2004
Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. British journal of cancer, 2005, Feb-28, Volume: 92, Issue:4 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA Fragmentation; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Topoisomerase I Inhibitors; Topotecan	2005
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer research, 2005, Feb-15, Volume: 65, Issue:4 Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan	2005
Augmenting tumor sensitivity to topotecan by transient hypoxia. Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:5 Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Small Cell; Cell Hypoxia; Cell Line, Tumor; Central Nervous System Neoplasms; Glioblastoma; Glucose Transporter Type 1; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Topotecan; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2005
Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer biology & therapy, 2005, Volume: 4, Issue:6 Topics: Administration, Oral; Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Carcinoma, Small Cell; DNA, Neoplasm; Female; Gene Frequency; Genotype; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Ovarian Neoplasms; Pharmacogenetics; Pilot Projects; Polymorphism, Single Nucleotide; Prospective Studies; Topotecan; Tumor Cells, Cultured	2005
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer research, 2005, Aug-01, Volume: 65, Issue:15 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan	2005
Topotecan: weighing in when there are many options. The oncologist, 2005, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Palliative Care; Topotecan	2005
Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. Clinical lung cancer, 2005, Volume: 7, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome	2005
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:5 Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan	2006
Reponses to topoisomerase-I inhibitors in extensive small-cell lung cancer: chance or chromosomes? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-01, Volume: 24, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Enzyme Inhibitors; Etoposide; Humans; Lung Neoplasms; Topoisomerase I Inhibitors; Topotecan	2006
Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Topotecan	2006
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments]. Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1 Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan	2006
[Is small cell lung cancer an orphan disease?]. Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1 Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Prevalence; Randomized Controlled Trials as Topic; Sex Factors; Thalidomide; Topotecan; Vincristine	2006
Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine. Cancer biology & therapy, 2006, Volume: 5, Issue:8 Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; DNA Damage; DNA-Binding Proteins; Flow Cytometry; Fluorescent Antibody Technique; Histones; HL-60 Cells; Humans; Lung Neoplasms; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Proteins	2006
Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 54, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Dyspnea; Fatal Outcome; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Pulmonary Alveoli; Pulmonary Fibrosis; Respiratory Insufficiency; Topotecan	2006
Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays. Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2006, Nov-01, Volume: 69, Issue:11 Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Transitional Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cost Control; Drug Screening Assays, Antitumor; Electronics; Humans; Lab-On-A-Chip Devices; Laser Scanning Cytometry; Lung Neoplasms; Microchip Analytical Procedures; Microscopy, Fluorescence; Mitoxantrone; Radio Waves; Ribonucleases; Topotecan	2006
Topotecan more effective than supportive care. The Lancet. Oncology, 2007, Volume: 8, Issue:1 Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Small Cell; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Survival Rate; Topotecan	2007
Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan	2007
Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Endpoint Determination; Etoposide; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Patient Compliance; Salvage Therapy; Topotecan	2008
Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies. The Journal of pharmacology and experimental therapeutics, 2008, Volume: 324, Issue:1 Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Line, Tumor; Cell Movement; Female; Humans; Indoles; Integrin alphaVbeta3; Lung Neoplasms; Mice; Mice, Nude; Topotecan; Vacuolar Proton-Translocating ATPases; Wound Healing; Xenograft Model Antitumor Assays	2008
Small-cell lung cancer, getting smaller but still difficult to treat. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:2 Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cranial Irradiation; Humans; Lung Neoplasms; Radiotherapy, Adjuvant; Recurrence; Topotecan	2008
Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer. Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Male; Multiple Myeloma; Neoplasms, Second Primary; Taxoids; Topotecan; Vinblastine; Vinorelbine	2008
[Therapeutic and adverse effects of topotecan combined with cisplatin for treatment of advanced squamous cell lung cancer and head and neck cancer]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Topotecan; Treatment Outcome; Young Adult	2008
Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. British journal of cancer, 1995, Volume: 72, Issue:2 Topics: Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carbon Radioisotopes; Carcinoma, Small Cell; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Isoenzymes; Lung Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1995
SEQPWR and SEQOPR: computer programs for design of maximum information trials based on group sequential logrank tests. Computer methods and programs in biomedicine, 1995, Volume: 46, Issue:2 Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Etoposide; Feasibility Studies; Follow-Up Studies; Humans; Linear Models; Lung Neoplasms; Programming Languages; Research Design; Sensitivity and Specificity; Software; Survival Rate; Topotecan	1995
Interaction of ionizing radiation with topotecan in two human tumor cell lines. International journal of cancer, 1996, May-03, Volume: 66, Issue:3 Topics: Antineoplastic Agents; Blotting, Northern; Brain Neoplasms; Camptothecin; Cell Line; Cell Survival; DNA Topoisomerases, Type I; Dose-Response Relationship, Radiation; Gene Expression; Glioblastoma; Humans; Lung Neoplasms; Radiation, Ionizing; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1996
Topotecan demonstrates significant activity in small-cell lung cancer. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Remission Induction; Topotecan	1996
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Topotecan	1996
Topotecan demonstrates significant activity in recurrent small-cell lung cancer. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan	1996
Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyclophosphamide; DNA Fragmentation; DNA, Neoplasm; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Topotecan	1997
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. British journal of cancer, 1997, Volume: 75, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione; Humans; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Taxoids; Topotecan; Tumor Cells, Cultured	1997
DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. International journal of cancer, 1997, Aug-07, Volume: 72, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Water	1997
Evaluation of treatment of recurrent small-cell lung cancer. Hospital medicine (London, England : 1998), 1999, Volume: 60, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Humans; Lung Neoplasms; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Topotecan; Vincristine	1999
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity. International journal of oncology, 1999, Volume: 15, Issue:4 Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured	1999
Circulating progenitor cell release and functional characterization after topotecan plus G-CSF and erythropoietin in small cell lung cancer patients. International journal of oncology, 1999, Volume: 15, Issue:4 Topics: Adult; Aged; Antigens, CD34; Apoptosis; Bromodeoxyuridine; Carcinoma, Small Cell; Cell Cycle; Drug Therapy, Combination; Erythropoietin; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukocyte Count; Lung Neoplasms; Middle Aged; Platelet Count; Recombinant Proteins; Time Factors; Topotecan	1999
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Immunohistochemistry; Lung Neoplasms; Topotecan; Tumor Cells, Cultured	1999
Lack of squamous cell lung carcinoma in vitro chemosensitivity to various drug regimens in the adenosine triphosphate cell viability chemosensitivity assay. Acta biochimica Polonica, 1999, Volume: 46, Issue:2 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Middle Aged; Pilot Projects; Topotecan; Tumor Cells, Cultured	1999
Topotecan--a new treatment option in the therapy of brain metastases of lung cancer. Frontiers of radiation therapy and oncology, 1999, Volume: 33 Topics: Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Topotecan	1999
Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. International journal of oncology, 1999, Volume: 15, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Survival Analysis; Survival Rate; Time Factors; Topotecan; Treatment Outcome	1999
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Caspase 8; Caspase 9; Caspases; Cisplatin; Deoxycytidine; Fas Ligand Protein; fas Receptor; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Lung Neoplasms; Membrane Glycoproteins; Paclitaxel; Recombinant Proteins; Signal Transduction; Topotecan; Transfection; Tumor Cells, Cultured	2000
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:1 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine	2000
Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer research, 2000, Jun-01, Volume: 60, Issue:11 Topics: Animals; Breast Neoplasms; Camptothecin; Cell Cycle; Chromatography, Gel; Chromatography, High Pressure Liquid; Dextrans; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Female; HeLa Cells; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prodrugs; Rats; Rats, Wistar; Time Factors; Tissue Distribution; Topotecan; Tumor Cells, Cultured	2000
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay	2000
Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer research, 2000, Sep-15, Volume: 60, Issue:18 Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antineoplastic Agents; Apoptosis; Caspases; Enzyme Activation; Enzyme Inhibitors; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Topotecan; Transfection; Tumor Cells, Cultured	2000
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:18 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Sesquiterpenes; Topotecan; Transplantation, Heterologous	2000
Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer research, 2000, Dec-15, Volume: 60, Issue:24 Topics: Adaptor Proteins, Signal Transducing; Amino Acid Chloromethyl Ketones; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cisplatin; Cytochrome c Group; Cytosol; Deoxycytidine; DNA, Complementary; Fas-Associated Death Domain Protein; Gemcitabine; Genes, Dominant; Humans; Inhibitory Concentration 50; Jurkat Cells; Lung Neoplasms; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Spectrometry, Fluorescence; Topotecan; Transfection; Tumor Cells, Cultured	2000
Improvement of therapeutic index of low-dose topotecan delivered per os. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Humans; Injections, Intravenous; Lung Neoplasms; Mice; Mice, Nude; Topotecan; Xenograft Model Antitumor Assays	2000
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2001, Volume: 32, Issue:2 Topics: Amino Acid Substitution; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Isoenzymes; Ki-67 Antigen; Life Tables; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Mutation, Missense; Neoplasm Proteins; Paclitaxel; Point Mutation; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Teniposide; Topotecan; Treatment Outcome; Vault Ribonucleoprotein Particles	2001
Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anti-cancer drugs, 2001, Volume: 12, Issue:4 Topics: Aminoquinolines; Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Indenes; Inhibitory Concentration 50; Injections, Intraperitoneal; Injections, Intravenous; Isoenzymes; Lung Neoplasms; Mice; Mice, Nude; Phenazines; Remission Induction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001
Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice. International journal of radiation oncology, biology, physics, 2001, Jul-01, Volume: 50, Issue:3 Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma, Small Cell; Combined Modality Therapy; Glioblastoma; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Oxygen; Radiation Tolerance; Topotecan; Xenograft Model Antitumor Assays	2001
Novel therapies in lung cancer management. An update on the role of topotecan. Oncology, 2001, Volume: 61 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Male; Prognosis; Topotecan; Treatment Outcome	2001
Topotecan is anti-angiogenic in experimental hepatoblastoma. Journal of pediatric surgery, 2002, Volume: 37, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Female; Hepatoblastoma; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	2002
[A case of recurrent small cell lung cancer with symptoms improved by nogitecan hydrochloride]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:5 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Topotecan	2002
Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. British journal of cancer, 2002, May-20, Volume: 86, Issue:10 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Drug Stability; Female; Glucuronides; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Prodrugs; Sex Factors; Solubility; Topotecan; Tumor Cells, Cultured; Weight Loss; Xenograft Model Antitumor Assays	2002